Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New anticancer agents in clinical development

J Eckardt1, G Eckhardt, M Villalona-Calero

  • 1Cancer Therapy and Research Center, Institute for Drug Development, San Antonio, Texas, USA.

Oncology (Williston Park, N.Y.)
|December 1, 1995
PubMed
Summary

New anticancer drugs targeting cancer cell biology are in clinical trials. These include topoisomerase I inhibitors, docetaxel, gemcitabine, thymidylate synthase inhibitors, and novel therapies like angiogenesis inhibitors and gene therapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose exploration.

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same author

Clinically decisive (dis)agreement in multidisciplinary team assessment of esophageal squamous cell carcinoma; a prospective, national, multicenter study.

Acta oncologica (Stockholm, Sweden)·2021
Same author

A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors.

Annals of oncology : official journal of the European Society for Medical Oncology·2018
Same author

Phase I study of the novel Cdc2/CDK1 and AKT inhibitor terameprocol in patients with advanced leukemias.

Investigational new drugs·2014
Same author

Open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of intravenously administered CNF1010 (17-(allylamino)-17-demethoxygeldanamycin [17-AAG]) in patients with solid tumors.

Cancer chemotherapy and pharmacology·2013
Same author

Population screening for the mutation associated with osteogenesis imperfecta in dachshunds.

The Veterinary record·2013

Area of Science:

  • Oncology
  • Pharmacology
  • Biochemistry

Background:

  • Advances in cancer cell biology and biochemistry drive the development of novel antineoplastic agents.
  • Existing and emerging cancer therapies are crucial for improving patient outcomes.

Purpose of the Study:

  • To review promising new antineoplastic compounds currently in clinical trials.
  • To discuss novel therapeutic strategies beyond traditional chemotherapy.

Main Methods:

  • Review of current literature on anticancer drug development.
  • Categorization of new agents based on their mechanism of action.

Main Results:

  • Several classes of new antineoplastic drugs are progressing through clinical trials.

Related Experiment Videos

  • Notable examples include topoisomerase I inhibitors (e.g., irinotecan, topotecan) and paclitaxel analogs (e.g., docetaxel).
  • Other agents discussed include gemcitabine, thymidylate synthase inhibitors, angiogenesis inhibitors, differentiating agents, signal transduction inhibitors, and gene therapy.

    • Conclusions:

    • The pipeline for cancer therapeutics is robust, with diverse mechanisms of action.
    • These novel agents represent significant advancements in the fight against cancer.